Opthea Data for OPT-302 in Combination With Ranibizumab for PCV Presented at ARVO

Opthea announced that clinical data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The presentation, titled “Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy,” was held on Sunday, May 1, 2022, and appeared in a session on clinical and translational research and AMD therapies excluding anti-VEGF. Jason Slakter, MD, clinical professor in the department of ophthalmology at NYU Grossman School of Medicine, presented.

“We are pleased to present and share these clinical findings with the global vision research community at the ARVO 2022 annual meeting,” said Dr. Megan Baldwin, CEO of Opthea. “We have received positive feedback on the potential utility of OPT-302 combination therapy for patients with PCV lesions and we look forward to evaluating additional data which is being obtained from the ongoing OPT-302 phase 3 ShORe and COAST trials which are expected to enroll a significant number of treatment-naïve patients with PCV."

The ARVO poster presented results of a prespecified subgroup analysis of subjects with Polypoidal Choroidal Vasculopathy (PCV type CNV) enrolled in the phase 2b randomized, sham-controlled study of patients with treatment-naive exudative AMD. In this study, subjects received either monotherapy with ranibizumab (Lucentis) or combination therapy with ranibizumab and one of two doses of OPT-302. Of the 366 participants, 66 (18%) were identified as having PCV lesions at baseline based on multimodal imaging analysis of color fundus photography, fluorescein angiography and SD-OCT.

OPT-302 (2.0 mg) used in combination with ranibizumab (0.5 mg) achieved superior visual acuity gains and anatomic improvements compared to monthly ranibizumab monotherapy in these subjects with PCV type CNV. Specifically, following OPT-302 combination therapy over the 6 months of the study, an additional 6.7 letter gain was achieved over ranibizumab monotherapy. A greater proportion of patients gained ≥ 10 and ≥15 letters from baseline, or achieved 20/40 vision or better, while fewer participants lost 5 letters or more of vision.

A copy of the poster is available on Presentations page of the Opthea website: www.opthea.com.